Navigation Links
Interleukin Genetics Announces Strategic Divestment of Alan James Group
Date:7/2/2009

WALTHAM, Mass., July 2 /PRNewswire-FirstCall/ -- Interleukin Genetics, Inc. (NYSE Amex: ILI) announced today that on June 30, 2009 it executed an agreement to sell the Alan James Group assets of its subsidiary AJG Brands, Inc. to Pep Products, Inc., a subsidiary of Nutraceutical Corporation, for approximately $4.6 million in cash. The transaction was completed following the close of business on June 30th.

"While the Alan James Group business saw an increase in sales during the last fiscal year and we were able to introduce two new products to the market in the past seven months, this transaction allows us to focus our efforts on growing our core genetic testing business. The sale of AJG provides non-dilutive cash to continue development and promotion of our genetic testing services and products including our new brand of Inherent Health tests," said Lewis H. Bender, CEO, Interleukin Genetics.

About Interleukin Genetics

Interleukin Genetics, Inc. (NYSE Amex: ILI) develops and markets genetic tests, including its new brand of Inherent Health genetic test products that empower consumers to maintain health and wellness, and assists pharmaceutical companies in the development and marketing of targeted therapeutics. The Company leverages its research, intellectual property, and biomarker development experience to facilitate the emerging personalized health market. Interleukin Genetics is headquartered in Waltham, MA. For more information please visit www.ilgenetics.com.

Certain statements contained herein are "forward-looking" statements including statements regarding the Company's ability to develop genetic tests that identify genetic variations that
'/>"/>

SOURCE Interleukin Genetics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. Interleukin Genetics Launches Inherent Health Brand of Genetic Tests Offering Clear and Personalized Insights to Wellness
2. Interleukin Genetics to Present Research Linking Perilipin Genes to Diet Response at the ADA Annual Meeting
3. Interleukin Genetics Reports First Quarter 2009 Financial Results
4. NYSE Amex Accepts Interleukin Genetics Plan to Meet Continued Listing Standards
5. Interleukin Genetics to Chair Expert Panel Discussion on Use of Biomarkers in Drug Development at BIO Convention
6. Interleukin Genetics Announces Conference Call to Discuss First Quarter 2009 Results
7. Interleukin Genetics Grants LABEC Pharma a License for Sales and Distribution of Its Heart Health Genetic Test
8. Interleukin Genetics Receives NYSE Amex Staff Determination, Requests Oral Hearing Before the Listing Qualifications Panel
9. Interleukin Genetics Announces Conference Call to Discuss Fourth Quarter 2008 Results
10. Interleukin Genetics to Present at G-2 Reports Molecular Diagnostic Conference
11. Interleukin Genetics Submits Plan to Regain Compliance with Continued Listing Standards
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... Harbor, NY For decades, health-conscious people around the ... in antioxidants, figuring this was one of the paths ... , Yet clinical trials of antioxidant supplements have repeatedly ... to reduce their cancer risk. Virtually all such ... cancer. In fact, in several trials antioxidant supplementation ...
(Date:7/10/2014)... at sarcomas research group at the Bellvitge Biomedical Research ... have been tested in 19 patients a new therapeutic ... which indicate that the new treatment could stabilize the ... in the British Journal of Cancer ., ... and complex since there are several subtypes. It can ...
(Date:7/10/2014)... a new drug could prove useful in treating small cell ... , Scientists from the Cancer Research UK Manchester Institute, based ... Cancer Research Centre, teamed up with experts at AstraZeneca, as ... drug known as AZD3965 - on small cell lung ... Clinical Cancer Research , also helps identify which patients are ...
(Date:7/9/2014)... WASHINGTON, DC (July 10, 2014) If you think winning ... fun for kids think again: Winning along with other mental ... each of which falls into one of 11 big fun ... that winning is all important when it comes to the ... identify and quantify what goes into this elusive conceptuntil now. ...
(Date:7/9/2014)... of low back pain are not linked to weather ... and precipitation. Findings published in Arthritis Care & ... Rheumatology (ACR), indicate that the risk of low back ... gusts, but was not clinically significant. , According ... low back pain at some point in their life, ...
Breaking Medicine News(10 mins):Health News:How antioxidants can accelerate cancers, and why they don't protect against them 2Health News:New therapeutic combination to slow resistant sarcomas 2Health News:New drug active against most aggressive type of lung cancer cells 2Health News:Being a good sport ranks as the top 'fun' factor in study of youth sports 2Health News:Being a good sport ranks as the top 'fun' factor in study of youth sports 3Health News:Low back pain? Don't blame the weather 2
... in U.S., Canada, study says , FRIDAY, April 16 ... places across the United States and Canada could save ... die of cardiac arrest each year, researchers report. , ... in more limited setting, such as casinos or airports, ...
... Inserting new valve within the valve might help high-risk ... -- If an artificial heart valve derived from a ... implanting a mechanical valve inside the artificial valve could ... and opened, the new valve opens and functions similarly ...
... brain lesions developed in patients taking Lipitor than placebo, ... Cholesterol-lowering statin drugs may slow the progression of multiple ... 81 patients with early-stage MS randomly selected to take ... a placebo. After 12 months of treatment, 55.3 percent ...
... Cardiovascular disease appears to be a major risk factor ... -- People with atrial fibrillation, a form of abnormal heart ... Alzheimer,s disease, a new study finds. , The presence of ... especially among younger patients in the group studied, meaning under ...
... Mo. For seniors, dancing isn,t just for fun; ... by University of Missouri researchers found that participation in ... adults. Improved functionality among seniors can decrease their risk ... as dance-based therapy have the potential to significantly reduce ...
... ... ... Researchers at Drexel University College of Medicine have discovered that a certain type ... critical for cancer growth and movement. When researchers reduced and normalized the levels of this ...
Cached Medicine News:Health News:Public Defibrillators Save Lives 2Health News:Public Defibrillators Save Lives 3Health News:Cholesterol Drugs May Slow MS 2Health News:Abnormal Heart Rhythm Linked to Alzheimer's 2Health News:Abnormal Heart Rhythm Linked to Alzheimer's 3Health News:Dance therapy improves seniors' gait, balance, researcher finds 2Health News:Scientists Report Key Finding in Breast Cancer Research 2Health News:Scientists Report Key Finding in Breast Cancer Research 3
(Date:1/15/2014)... CAMBRIDGE, Mass. , Jan. 15, 2014  Zafgen, ... the unmet needs of severely obese patients, today ... of beloranib, a selective inhibitor of methionine aminopeptidase ... a severe form of genetic obesity.  These results ...
(Date:1/14/2014)... Jan. 14, 2014  Luminex Corporation (Nasdaq: LMNX ) ... fourth quarter of 2013 on Monday, February 3, 2014. A ... the close of trading. (Logo: http://photos.prnewswire.com/prnh/20100104/LUMINEXLOGO ... discuss the operating highlights and financial results for the fourth ...
(Date:1/14/2014)... Healthcare Services, Inc. ("DHS"), a portfolio company of GMH Ventures ... Equipment, Inc. ("Progressive") of Clarion, PA ... not disclosed. Progressive is a full service ... sleep, mobility, and respiratory products to customers in the western ...
Breaking Medicine Technology:Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 2Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 3Dynamic Healthcare Services Completes Progressive Home Medical Equipment of Clarion, PA Investment 2Dynamic Healthcare Services Completes Progressive Home Medical Equipment of Clarion, PA Investment 3
... 7, 2011 In an address to ... John C. Lechleiter, Ph.D., chairman, president and chief executive ... build a new level of trust between the biopharmaceutical ... can harness innovation to help meet growing health care ...
... 2011 Merit Medical Systems, Inc. (NASDAQ: MMSI ... used primarily in cardiology, radiology and endoscopy, announced today that ... quarter ended June 30, 2011, after the close of the ... will hold its investor conference call on the same day ...
Cached Medicine Technology:Lilly CEO Calls for Improved Dialogue in Germany Between Industry and the Government and Health Care System 2Lilly CEO Calls for Improved Dialogue in Germany Between Industry and the Government and Health Care System 3Lilly CEO Calls for Improved Dialogue in Germany Between Industry and the Government and Health Care System 4
Non-Illuminated Trial Lens Set is an attractive set of trial lenses worked to a high standard of accuracy....
Trial Lens Sets....
... disc test (P/N LD15C) include a durable ... instructions. P/N LD15C also includes a Plexiglas ... covers for the test subjects fingers ( ... color discs). Beware that these finger cots ...
Opti-Free Express multi-purpose disinfecting solution lasting comfort No Rub formula provides triple action protection for your contact lenses....
Medicine Products: